TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours

British Journal of Cancer

Volumn 109, Issue 2, 2013, Pages 497-501

  Griewank, K G ^a   Murali, R ^b   Schilling, B ^a   Scholz, S ^a   Sucker, A ^a   Song, M ^a   Susskind D ^c   Grabellus, F ^a   Zimmer, L ^a   Hillen, U ^a   Steuhl, K P ^a   Schadendorf, D ^a   Westekemper, H ^a   Zeschnigk, M ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

cancer genetics; dermatology; melanoma; ophthalmology; telomerase

Indexed keywords

B RAF KINASE; TELOMERASE REVERSE TRANSCRIPTASE;

AGED; ARTICLE; CANCER STAGING; CHROMOSOME 3; CLINICAL ARTICLE; CONJUNCTIVA TUMOR; CONJUNCTIVAL MELANOMA; CUTANEOUS MELANOMA; DISEASE FREE SURVIVAL; DISOMY; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; HUMAN TISSUE; MALE; MELANOMA; MONOSOMY; ONCOGENE N RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; SEQUENCE ANALYSIS; ULTRAVIOLET RADIATION; UVEA MELANOMA; WILD TYPE;

AGED; COHORT STUDIES; CONJUNCTIVAL NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENETIC ASSOCIATION STUDIES; GTP PHOSPHOHYDROLASES; HUMANS; MALE; MELANOMA; MEMBRANE PROTEINS; MUTATION; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS B-RAF; TELOMERASE; UVEAL NEOPLASMS;

EID: 84881114904     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.312     Document Type: Article

References (36)

1. Ball NJ, Yohn JJ, Morelli JG, Norris DA, Golitz LE, Hoeffler JP (1994) Ras mutations in human melanoma: A marker of malignant progression. J Invest Dermatol 102(3): 285-290.
2. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26): 2507-2516.
3. Curtin JA, Busam K, Pinkel D, Bastian BC (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24(26): 4340-4346.
4. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Brocker EB, LeBoit PE, Pinkel D, Bastian BC (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353(20): 2135-2147.
5. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892): 949-954.
6. Flaherty KT, Hodi FS, Fisher DE (2012) From genes to drugs: Targeted strategies for melanoma. Nat Rev Cancer 12(5): 349-361.
7. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris 3rd HA, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367(18): 1694-1703.
8. Gear H, Williams H, Kemp EG, Roberts F (2004) BRAF mutations in conjunctival melanoma. Investig Ophthalmol Vis Sci 45(8): 2484-2488.
9. Goldenberg-Cohen N, Cohen Y, Rosenbaum E, Herscovici Z, Chowers I, Weinberger D, Péer J, Sidransky D (2005) T1799 BRAF mutations in conjunctival melanocytic lesions. Investig Ophthalmol Vis Sci 46(9): 3027-3030.
10. Griewank K, Westekemper H, Murali R, Mach M, Schilling B, Wiesner T, Schimming T, Livingstone E, Sucker A, Grabellus F, Metz C, Susskind D, Hillen U, Speicher MR, Woodman SE, Steuhl KP, Schadendorf D (2013) Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas. Clin Cancer Res, in press; doi: 10.1158/1078-0432.CCR-13- 0163.
11. Guenel P, Laforest L, Cyr D, Fevotte J, Sabroe S, Dufour C, Lutz JM, Lynge E (2001) Occupational risk factors, ultraviolet radiation, and ocular melanoma: A case-control study in France. Cancer Causes Control 12(5): 451-459.
12. Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, Council ML, Matatall KA, Helms C, Bowcock AM (2010) Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330(6009): 1410-1413.
13. Harbour JW, Roberson ED, Anbunathan H, Onken MD, Worley LA, Bowcock AM (2013) Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat Genet 45(2): 133-135.
14. Harooni H, Schoenfield LR, Singh AD (2011) Current appraisal of conjunctival melanocytic tumors: Classification and treatment. Future Oncol 7(3): 435-446.
15. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller Jr. WH, Kaempgen E, Martin-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB (2012) Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, openlabel, phase 3 randomised controlled trial. Lancet 380(9839): 358-365.
16. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, Dicara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, Voet D, Saksena G, Stransky N, Onofrio RC, Winckler W, Ardlie K, Wagle N, Wargo J, Chong K, Morton DL, Stemke-Hale K, Chen G, Noble M, Meyerson M, Ladbury JE, Davies MA, Gershenwald JE, Wagner SN, Hoon DS, Schadendorf D, Lander ES, Gabriel SB, Getz G, Garraway LA, Chin L (2012) A landscape of driver mutations in melanoma. Cell 150(2): 251-263.
17. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D, Kumar R (2013) TERT promoter mutations in familial and sporadic melanoma. Science 339(6122): 959-961.
18. Houben R, Becker JC, Kappel A, Terheyden P, Brocker EB, Goetz R, Rapp UR (2004) Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog 3(1): 6.
19. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339(6122): 957-959.
20. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz Jr. LA, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, Mandahl N, Meeker AK, Mertens F, Netto GJ, Rasheed BA, Riggins GJ, Rosenquist TA, Schiffman M, Shih IM, Theodorescu D, Torbenson MS, Velculescu VE, Wang TL, Wentzensen N, Wood LD, Zhang M, McLendon RE, Bigner DD, Kinzler KW, Vogelstein B, Papadopoulos N, Yan H (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 110(15): 6021-6026.
21. Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, Cheng E, Davis MJ, Goh G, Choi M, Ariyan S, Narayan D, Dutton-Regester K, Capatana A, Holman EC, Bosenberg M, Sznol M, Kluger HM, Brash DE, Stern DF, Materin MA, Lo RS, Mane S, Ma S, Kidd KK, Hayward NK, Lifton RP, Schlessinger J, Boggon TJ, Halaban R (2012) Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 44(9): 1006-1014.
22. Lake SL, Jmor F, Dopierala J, Taktak AF, Coupland SE, Damato BE (2011) Multiplex ligation-dependent probe amplification of conjunctival melanoma reveals common BRAF V600E gene mutation and gene copy number changes. Investig Ophthalmol Vis Sci 52(8): 5598-5604.
23. Onken MD, Worley LA, Ehlers JP, Harbour JW (2004) Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 64(20): 7205-7209.
24. Pane AR, Hirst LW (2000) Ultraviolet light exposure as a risk factor for ocular melanoma in Queensland, Australia. Ophthalmic Epidemiol 7(3): 159-167.
25. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD, Varela I, Lin ML, Ordonez GR, Bignell GR, Ye K, Alipaz J, Bauer MJ, Beare D, Butler A, Carter RJ, Chen L, Cox AJ, Edkins S, Kokko-Gonzales PI, Gormley NA, Grocock RJ, Haudenschild CD, Hims MM, James T, Jia M, Kingsbury Z, Leroy C, Marshall J, Menzies A, Mudie LJ, Ning Z, Royce T, Schulz-Trieglaff OB, Spiridou A, Stebbings LA, Szajkowski L, Teague J, Williamson D, Chin L, Ross MT, Campbell PJ, Bentley DR, Futreal PA, Stratton MR (2010) A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463(7278): 191-196.
26. Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jöckel KH, Becher R (1996) Prognostic implications of monosomy 3 in uveal melanoma. Lancet 347(9010): 1222-1225.
27. Shields CL, Markowitz JS, Belinsky I, Schwartzstein H, George NS, Lally SE, Mashayekhi A, Shields JA (2011) Conjunctival melanoma: Outcomes based on tumor origin in 382 consecutive cases. Ophthalmology 118(2): 389-95 e1-2.
28. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. Cancer J Clin 62(1): 10-29.
29. Singh AD, Bergman L, Seregard S (2005) Uveal melanoma: Epidemiologic aspects. Ophthalmol Clin North Am 18(1): 75-84viii.
30. Singh AD, Rennie IG, Seregard S, Giblin M, McKenzie J (2004) Sunlight exposure and pathogenesis of uveal melanoma. Surv Ophthalmol 49(4): 419-428.
31. Spendlove HE, Damato BE, Humphreys J, Barker KT, Hiscott PS, Houlston RS (2004) BRAF mutations are detectable in conjunctival but not uveal melanomas. Melanoma Res 14(6): 449-452.
32. Thomas S, Putter C, Weber S, Bornfeld N, Lohmann DR, Zeschnigk M (2012) Prognostic significance of chromosome 3 alterations determined by microsatellite analysis in uveal melanoma: A long-term follow-up study. Br J Cancer 106(6): 1171-1176.
33. Tschentscher F, Hüsing J, Hölter T, Kruse E, Dresen IG, Jöckel KH, Anastassiou G, Schilling H, Bornfeld N, Horsthemke B, Lohmann DR, Zeschnigk M (2003) Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res 63(10): 2578-2584.
34. Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM, Simpson EM, Barsh GS, Bastian BC (2009) Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457(7229): 599-602.
35. Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, Obenauf AC, Wackernagel W, Green G, Bouvier N, Sozen MM, Baimukanova G, Roy R, Heguy A, Dolgalev I, Khanin R, Busam K, Speicher MR, O'Brien J, Bastian BC (2010) Mutations in GNA11 in uveal melanoma. N Engl J Med 363(23): 2191-2199.
36. Zembowicz A, Mandal RV, Choopong P (2010) Melanocytic lesions of the conjunctiva. Arch Pathol Lab Med 134(12): 1785-1792.